Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma ( LNH 03-1 B )

N. Ketterer1*, B. Coiffier2, C. Thieblemont3, C. Fermé4, J. Brière5, O. Casasnovas6, S. Bologna7, B. Christian8, T. Connerotte9, C. Récher10, D. Bordessoule11, C. Fruchart12, R. Delarue13, C. Bonnet14, F. Morschhauser15, B. Anglaret16, C. Soussain17, B. Fabiani18, H. Tilly19 & C. Haioun20 Department of Oncology, University Hospital, Lausanne, Switzerland; Department of Hematology, Lyon Sud University Hospital, Pierre-Bénite; Department of Hematology, St Louis University Hospital, Paris; Department of Hematology, Gustave Roussy Institute, Villejuif; Department of Pathology, St Louis University Hospital, Paris; Department of Hematology, University Hospital, Dijon; Department of Hematology, University Hospital, Nancy-Brabois, Vandoeuvre; Department of Hematology, Bon Secours Hospital, Metz, France; Department of Hematology, St Luc University Hospital, Bruxelles, Belgium; Department of Hematology, University Hospital, Toulouse; Department of Hematology, University Hospital Limoges, Limoges; Department of Hematology, François Baclesse Center, Caen; Department of Hematology, Necker University Hospital, Paris, France; Department of Hematology, Sart Tilman University Hospital, Liège, Belgium; Department of Hematology, Claude Huriez University Hospital, Lille; Department of Hematology, University Hospital, Valence; Department of Hematology, René Huguenin Hospital, Saint Cloud; Department of Pathology, Saint-Antoine Hospital, Paris; Department of Hematology, Henri Becquerel Center, Rouen; Department of Hematology, Henri Mondor University Hospital, Créteil, France

[1]  T. Molina,et al.  A Prospective Randomized Study Comparing Dose Intensive Immunochemotherapy with R-ACVBP vs Standard R-CHOP In Younger Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study LNH03-2B , 2010 .

[2]  N. Schmitz,et al.  Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL) after dose-dense rituximab: Results of the DENSE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) , 2008 .

[3]  L. Rimsza,et al.  Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  T. Molina,et al.  CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Gascoyne,et al.  Clinical Trials and Observations , 2005 .

[6]  A. López-Guillermo,et al.  CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.

[7]  L. Staudt,et al.  Primary Mediastinal Large B-Cell Lymphoma (PMBL) Outcome Is Significantly Improved by the Addition of Rituximab to Dose Adjusted (DA)-EPOCH and Overcomes the Need for Radiation. , 2005 .

[8]  T. Molina,et al.  ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. , 2005, The New England journal of medicine.

[9]  J. Earle,et al.  Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[11]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Fisher,et al.  Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. , 1998, The New England journal of medicine.

[13]  J. Connors,et al.  Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. , 1987, Annals of internal medicine.

[14]  J. Kinzie,et al.  Survival of patients with localized diffuse histiocytic lymphoma. , 1981, Blood.

[15]  E. Freireich,et al.  Management with chemotherapy only of stage I and II malignant lymphoma of aggressive histologic types , 1980, Cancer.